Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
161actual
Sites
40
Countries
Japan, Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-15 | actual | When the study began enrolling |
| Primary completion | 2025-11-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-10 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bipolar I Disorder
- Bipolar II Disorder
Interventions
- Drug: ABBV-932
- Drug: Placebo for ABBV-932
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
measured Up to Week 6
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed